Chinese clinical-stage biopharma firm Akeso has resubmitted a draft prospectus with the Hong Kong stock exchange on Monday, exactly two months after the city board rejected its original application for an initial public offering (IPO).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
